LPS-induced chemokine and cytokine profiles

LPS-induced chemokine and cytokine profiles refer to the coordinated release of pro-inflammatory signaling molecules by innate immune cells, such as macrophages and monocytes, following exposure to Lipopolysaccharide (LPS). LPS, an endotoxin from Gram-negative bacteria, acts as a ligand for the Toll-like receptor 4 (TLR4)/MD-2 complex, initiating a signaling cascade that involves MyD88 and TRIF adapter proteins (Beutler, 2004). This process culminates in the activation of transcription factors like NF-kappaB, which drive the expression of cytokines such as TNF-alpha, IL-6, and IL-1 beta, as well as chemokines like CCL2 and CXCL8 (Chaudhry et al., 2013). In the pharmaceutical industry, these profiles are extensively used as a phenotypic assay readout to screen for anti-inflammatory compounds or to validate the target engagement of TLR4 inhibitors. Although the profile is a multi-component biological response rather than a single molecular target, it is central to the pathophysiology of sepsis, endotoxemia, and various acute inflammatory states. Therapeutic strategies often focus on dampening this profile to prevent the "cytokine storm" associated with severe infections. Drugs like TAK-242 (Resatorvid) specifically target the TLR4 receptor to suppress these profiles, while corticosteroids provide broader suppression of the inflammatory response (Matsunaga et al., 2011).

Other names

LPS-induced inflammatory responseEndotoxin-induced cytokine productionTLR4-mediated cytokine profileLPS-induced cytokine storm

Drugs modulate these profiles by inhibiting the Toll-like receptor 4 (TLR4) signaling complex, blocking downstream transcription factors such as NF-kappaB and AP-1, or directly neutralizing the resulting cytokines.